|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
11 April 2016 |
|
Main ID: |
NCT00709917 |
|
Date of registration:
|
30/06/2008 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes
REPAMET |
|
Scientific title:
|
Observational Study Investigating the Efficacy of Switching From Metformin Monotherapy to a Dual Therapy of Metformin and Repaglinide on Glycaemic Control in Type 2 Diabetes |
|
Date of first enrolment:
|
March 2007 |
|
Target sample size:
|
2171 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT00709917 |
|
Study type:
|
Observational |
|
Study design:
|
Time Perspective: Prospective
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Belgium
|
Luxembourg
| | | | | | |
|
Contacts
|
|
Name:
|
Global Clinical Registry (GCR, 1452) |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Novo Nordisk A/S |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Type 2 diabetic patients with inadequate glycaemic control when received metformin
alone on maximal dose
- Signed informed consent
- Treatment in accordance with the summary of product characterisation
Exclusion Criteria:
- Any contraindication to metformin or repaglinide
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Diabetes Mellitus, Type 2
|
|
Diabetes
|
|
Intervention(s)
|
|
Drug: repaglinide
|
|
Primary Outcome(s)
|
|
Safety (number of hypoglycaemic incidents)
[Time Frame: After 10-20 weeks]
|
|
HbA1C
[Time Frame: After 10-20 weeks]
|
|
Secondary Outcome(s)
|
|
posology
[Time Frame: After 10-20 weeks]
|
|
lifestyle
[Time Frame: After 10-20 weeks]
|
|
FBG
[Time Frame: After 10-20 weeks]
|
|
safety
[Time Frame: After 10-20 weeks]
|
|
Secondary ID(s)
|
|
AGEE-1857
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|